BNP Paribas Financial Markets
SKYE icon

BNP Paribas Financial Markets’s Skye Bioscience SKYE Stock Holding History

BNP Paribas Financial Markets’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-510
Closed -$382 – 6178
2025
Q4 		$382 Hold
510
– – ﹤0.01% 5501
2025
Q3 		$2K Sell
510
-810
-61% -$3.06K ﹤0.01% 5171
2025
Q2 		$5.52K Buy
1,320
+302
+30% +$625 ﹤0.01% 4950
2025
Q1 		$1.62K Sell
1,018
-30,619
-97% -$83.6K ﹤0.01% 5015
2024
Q4 		$89.5K Sell
31,637
-15,780
-33% -$65.9K ﹤0.01% 4194
2024
Q3 		$185K Buy
47,417
+19,704
+71% +$111K ﹤0.01% 3276
2024
Q2 		$222K Buy
+27,713
New +$329K ﹤0.01% 3063

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

BNP Paribas Financial Markets's SKYE Position: Q1 2026 in Review

BNP Paribas Financial Markets sold out of Skye Bioscience (SKYE) in Q1 2026, closing a stake of 510 shares — an estimated $382 sold.

BNP Paribas Financial Markets first reported a position in SKYE in Q2 2024 and held it in 7 quarters. The position peaked at $222K in Q2 2024. 39 funds tracked by Wall St. Rank hold SKYE as of Q1 2026.

  • BNP Paribas Financial Markets reported no remaining Skye Bioscience position as of Q1 2026 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 510 Skye Bioscience shares in Q1 2026, an estimated $382.
  • BNP Paribas Financial Markets first reported a position in Skye Bioscience in Q2 2024 and held it in 7 quarters.
  • BNP Paribas Financial Markets's Skye Bioscience position peaked at $222K in Q2 2024.
  • 39 funds tracked by Wall St. Rank held Skye Bioscience as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.